Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
Submitted by
admin
on August 23, 2017 - 11:21am
Source:
Fierce Pharma
News Tags:
Pfizer
Eucrisa
DTC
eczema
Dupixent
Sanofi
Regeneron
Headline:
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
Do Not Allow Advertisers to Use My Personal information
